CUSIP
No. 141743 10 4
|
Page
2 of 13
|
1.
|
Name
of Reporting Persons.
Steven
G. Johnson
|
2.
|
Check
the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
|
3.
|
SEC
Use Only
|
4.
|
Source
of Funds
OO-Other
|
5.
|
Check
if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ☐
|
|
6.
|
Citizenship
or Place of Organization
United
States
|
Number
of Shares
Beneficially
Owned
by
Each Reporting
Person
With
|
7.
|
Sole
Voting Power
41,509,004(1)(2)(3)(4)
|
8.
|
Shared
Voting Power
-0-
|
9.
|
Sole
Dispositive Power
41,509,004(1)(2)(3)(4)
|
10.
|
Shared
Dispositive Power
-0-
|
11.
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
41,509,004(1)(2)(3)(4)
|
12.
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares
☐
|
13.
|
Percent
of Class Represented by Amount of Row (11)
25.1%(5)
|
14.
|
Type
of Reporting Person
IN
|
|
|
|
|
|
|
(1)
|
Includes
550,001 shares of Common Stock underlying warrants exercisable at any time.
|
|
(2)
|
Includes
24,421,743 shares of Common Stock underlying convertible notes convertible at any time.
|
|
(3)
|
Includes
766,667 shares of Common Stock underlying options exercisable within sixty days.
|
|
(4)
|
Includes
15,561,616 shares of Common Stock held by SJ Capital, LLC.
|
|
(5)
|
Based
on 139,380,748 shares of Common Stock outstanding as of May 15, 2018 as reported in the
Issuer’s Form 10-Q filed on May 15, 2018, and an additional 25,738,411
shares which would be outstanding if all of Mr. Johnson’s options exercisable
within sixty days, warrants and convertible notes were exercised or converted.
|
CUSIP
No. 141743 10 4
|
Page
3 of 13
|
1.
|
Name
of Reporting Persons.
SJ
Capital, LLC, a Delaware entity solely owned Steven G. Johnson (“SJ Capital”)
|
2.
|
Check
the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
|
3.
|
SEC
Use Only
|
4.
|
Source
of Funds
OO-Other
|
5.
|
Check
if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ☐
|
|
6.
|
Citizenship
or Place of Organization
United
States
|
Number
of Shares
Beneficially
Owned
by
Each Reporting
Person
With
|
7.
|
Sole
Voting Power
15,561,616
|
8.
|
Shared
Voting Power
-0-
|
9.
|
Sole
Dispositive Power
15,561,616
|
10.
|
Shared
Dispositive Power
-0-
|
11.
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
15,561,616
|
12.
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares
☐
|
13.
|
Percent
of Class Represented by Amount of Row (11)
11.2%(1)
|
14.
|
Type
of Reporting Person
OO
|
|
|
|
|
|
|
(1)
|
Based
on 139,380,748 shares of Common Stock outstanding as of May 15, 2018 as reported in the
Issuer’s Form 10-Q filed on May 15, 2018.
|
CUSIP
No. 141743 10 4
|
Page
4 of 13
|
This
Amendment No. 6 to Schedule 13D (the “Amendment”) amends and supplements the beneficial ownership statement on Schedule
13D originally filed with the Securities and Exchange Commission on September 29, 2010, as amended by subsequent Schedules 13D
filed on each of January 30, 2012, August 17, 2012, January 3, 2013, April 1, 2013 and February 19, 2015. This Amendment is being
filed to report amendments in Items 3, 5, 6 and 7.
Item
1. Security and Issuer
The
class of equity securities to which this Schedule 13D relates is the common stock, $.001 par value, of CareView Communications,
Inc., a Nevada corporation (“Company” or “Issuer”). The address of the principal executive office of the
Company is 405 State Highway 121, Suite B-240, Lewisville, TX 75067.
Item
2. Identity and Background.
(a)
Names: Steven G. Johnson and SJ Capital (the “Reporting Persons”).
(b)
Residence or Business Address of Reporting Persons:
405
State Highway 121, Suite B-240, Lewisville, TX 75067.
(c)
Present principal occupation or employment: Steven G. Johnson is President, Chief Executive Officer, Secretary
and Treasurer of the Company. Mr. Johnson also serves as one of the Company’s directors.
(d)
During the last five years, the Reporting Persons have not been convicted in a criminal proceeding (excluding
traffic violations or similar misdemeanors).
(e)
During the last five years, the Reporting Persons have not been a party to a civil proceeding of a judicial
or administrative body of competent jurisdiction which as a result of such proceeding was or is subject to a judgment, decree
or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities
laws or finding violation with respect to such laws.
(f)
Citizenship: United States of America.
CUSIP
No. 141743 10 4
|
Page
5 of 13
|
Item
3. Source and Amount of Funds or Other Consideration.
Item
3 is hereby amended and restated in its entirety as follows:
OO-Other
PF-Personal
Funds
AF-Affiliate
Acquisition
of Shares of the Issuer
On
September 28, 2007, CareView Communications, Inc., a Texas corporation (“CareView-TX”), its shareholders, and Ecogate,
Inc. entered into a Securities Exchange Agreement (the “Agreement”), pursuant to which Ecogate, Inc. issued 87,684,910
shares of its Common Stock to the CareView-TX shareholders in exchange for 100% of the outstanding stock of CareView-TX. Upon
the closing of the Agreement, the shares of CareView-TX owned by InvestSearch, LLC, an entity of which Mr. Johnson owned 22.5%
(“InvestSearch”), was exchanged for 11,104,334 shares of Ecogate, Inc. (Ecogate, Inc. subsequently changed its name
to CareView Communications, Inc., which is now a Nevada corporation and the Issuer.)
On
July 7, 2009, the members of InvestSearch agreed to distribute its 11,104,334 shares and Mr. Johnson, through SJ Capital, received
1,280,136 of those shares.
On
November 23, 2007, SJ Capital was transferred 12,038,175 shares of the Company’s Common Stock from Recap Group, LLC, an
entity solely owned by David Webb, in exchange for the transfer to Mr. Webb of cash and securities of non-affiliated companies
owned by Mr. Johnson. Mr. Webb served as a director of the Company at the time of the transfer.
On
November 11, 2008, the Company converted a loan from Sat-Net Communications, LLC, an entity of which Mr. Johnson owned 25% (“Sat-Net”),
in which aggregated principal and interest of $153,911.88 was converted into 295,984 shares of the Company’s Common Stock
at $0.52 per share. On June 1, 2010, the members of Sat-Net agreed to distribute its 295,984 shares and SJ Capital received 73,996
of those shares.
On
January 8, 2010, SJ Capital was transferred 1,023,403 shares of the Company’s Common Stock from an unaffiliated party in
a private transaction.
On
August 25, 2011, Mr. Johnson acquired 6,957 shares of the Company’s Common Stock from an unaffiliated party in a private
transaction.
On
August 15, 2012 and August 16, 2012, Mr. Johnson acquired 165,350 and 86,400 shares of the Company’s Common Stock, respectively,
from unaffiliated parties in a private transaction.
On
March 27, 2013, the Company executed a Securities Purchase Agreement (the “Purchase Agreement”) with multiple investors
(collectively, the “Investors”) relating to the sale and issuance of shares of the Company’s common stock and
warrants to purchase common stock in a private offering. At the closing on April 1, 2013, Mr. Johnson purchased 202,020 shares
of the Company’s Common Stock at a price of $0.495 per share for an aggregate purchase price of $100,000. Mr. Johnson did
not purchase any warrants thereunder.
CUSIP
No. 141743 10 4
|
Page
6 of 13
|
Between
November 20, 2014 and December 4, 2014, Mr. Johnson, through SJ Capital, purchased 400,000 shares of the Company’s Common
Stock in the market.
Between
November 19, 2015 and December 4, 2015, Mr. Johnson, through SJ Capital, purchased 120,000 shares of the Company’s Common
Stock in the market.
Between
June 2, 2016 and November 17, 2016, Mr. Johnson, through SJ Capital, purchased 2,200,000 shares of the Company’s Common
Stock in the market.
Disposition
of Shares of the Issuer
Between
November 2008 and September 29, 2010, Mr. Johnson, through SJ Capital, transferred an aggregate of 885,844 shares in private transactions.
On
December 15, 2010, Mr. Johnson, through SJ Capital, transferred 190,000 shares in a private transaction.
On
December 31, 2012, Mr. Johnson, through SJ Capital, transferred 750,000 shares in a private transaction.
Acquisition
of Derivative Securities of the Issuer
Non-Qualified
Stock Options (“Options”)
On
January 6, 2010, Mr. Johnson was issued an Option under the CareView Communications 2009 Stock Incentive Plan (the “2009
Plan”) for 50,000 underlying shares of the Company’s Common Stock at an exercise price of $0.52 per share. The underlying
shares of the ten-year Option vested immediately upon issuance. The Option was issued in exchange for the services provided by
Mr. Johnson for the year ended December 31, 2009 in his role as a director.
On
March 26, 2010, Mr. Johnson was issued an Option under the 2009 Plan for 50,000 underlying shares of the Company’s Common
Stock at an exercise price of $0.52 per share. The underlying shares of the ten-year Option vest on December 31, 2010. The Option
was issued in exchange for the services already provided and to be provided by Mr. Johnson for the year ending December 31, 2010
in his role as a director.
On
December 7, 2016, Mr. Johnson was issued an Option under the CareView Communications 2016 Stock Incentive Plan for 2,000,000 underlying
shares of the Company’s Common Stock at an exercise price of $0.10 per share. The ten-year Option vests as to 666,667 shares
on each of December 7, 2017 and December 7, 2018 and as to 666,666 shares on December 7, 2019. The Option was issued in exchange
for the services to be provided by Mr. Johnson in his role as Chief Executive Officer.
On
November 30, 2017, Mr. Johnson was issued an Option under the CareView Communications 2016 Stock Incentive Plan for 666,667 underlying
shares of the Company’s Common Stock at an exercise price of $0.11 per share. The ten-year Option vests as to 222,223 shares
on November 30, 2018 and as to 222,222 shares on each of November 30, 2019 and November 30, 2020. The Option was issued in exchange
for the services to be provided by Mr. Johnson in his role as Chief Executive Officer.
CUSIP
No. 141743 10 4
|
Page
7 of 13
|
Senior
Secured Convertible Note due 2025 and Common Stock Purchase Warrants
On
December 15, 2014, the Company entered into a Fifth Amendment to Note and Warrant Purchase Agreement (the “Fifth Amendment”)
with the HealthCor Parties and certain additional investors party thereto (such additional investors, the “Fifth Amendment
New Investors” and, collectively with the HealthCor Parties, the “Fifth Amendment Investors”) to sell and issue
(i) additional notes in the initial aggregate principal amount of $6,000,000, with a conversion price per share equal to $0.52
(subject to adjustment as described therein) (the “Fifth Amendment Supplemental Closing Notes”) and (ii) additional
warrants to purchase an aggregate of up to 3,692,308 shares of our Common Stock at an exercise price per share equal to $0.52
(subject to adjustment as described therein) (the “Fifth Amendment Supplemental Warrants”).
The
Fifth Amendment New Investors included all but one of the Company’s current directors as well as one of the Company’s
officers who is not also a director. The closing date of the transaction was February 17, 2015 (the “Fifth Amendment Supplemental
Closing Date”). On the Fifth Amendment Supplemental Closing Date, each of the Fifth Amendment Investors purchased the Fifth
Amendment Supplemental Closing Notes and the Fifth Amendment Supplemental Warrants for cash, payable by wire transfer in same
day funds to an account specified by the Company.
The
Purchase Agreement and Fifth Amendment provide that the Company grant to the Fifth Amendment Investors a security interest in
the assets of the Company as collateral for payment of the Fifth Amendment Supplemental Closing Notes, evidenced by that certain
Pledge and Security Agreement dated as of April 20, 2011 (the “Security Agreement”) and by that certain Intellectual
Property Security Agreement dated as of April 20, 2011 (the “IP Security Agreement”). On the Fifth Amendment Supplemental
Closing Date, the Company entered into an amended and restated Security Agreement and an amended and restated IP Security Agreement
in order, among other things, to add the Fifth Amendment New Investors as secured parties (such amended and restated agreements,
respectively the “Amended Security Agreement” and the “Amended IP Security Agreement”).
The
Purchase Agreement and the Fifth Amendment Supplemental Closing Notes also provide that the Company grant registration rights
to the Fifth Amendment Investors for the Common Stock into which the Fifth Amendment Supplemental Closing Notes may be converted
and that may be issued upon exercise of the Fifth Amendment Supplemental Warrants as provided for by that certain Registration
Rights Agreement dated as of April 20, 2011 (the “Registration Rights Agreement”).
Mr.
Johnson is one of the Fifth Amendment New Investors. On the Fifth Amendment Supplemental Closing Date, Mr. Johnson purchased a
Senior Secured Convertible Note in the amount of $650,000 which is immediately convertible into shares of the Company’s
Common Stock at a conversion price of $0.52 per share (subject to adjustment as described therein) and has a maturity date of
February 16, 2025. In connection therewith, Mr. Johnson was also issued Fifth Amendment Supplemental Warrants for the purchase
of 400,001 shares of the Company’s Common Stock at an exercise price per share equal to $0.52 (subject to adjustment as
described therein). The Fifth Amendment Supplemental Warrants were exercisable upon issuance and have an expiration date of February
17, 2025.
CUSIP
No. 141743 10 4
|
Page
8 of 13
|
Senior
Secured Convertible Note due February 2028 and Common Stock Purchase Warrants
On
February 23, 2018, the Company entered into an Eighth Amendment to Note and Warrant Purchase Agreement (the “Eighth Amendment”)
with the Fifth Amendment New Investors (the “Existing Investors”), an additional investor party thereto (such additional
investor, the “New Investor” and, collectively with the Existing Investors, the “Eighth Amendment Investors”)
and the HealthCor Parties (solely in their capacity as the majority holders approving the Eighth Amendment and not as investors),
pursuant to which the Company sold and issued, for an aggregate of $2,050,000 in cash, to the Eighth Amendment Investors on such
date (i) additional notes in the initial aggregate principal amount of $2,050,000, with a conversion price per share equal
to $0.05 (subject to adjustment as described therein) and a maturity date of February 22, 2028 (the “Eighth Amendment
Supplemental Closing Notes”) and (ii) additional warrants to purchase an aggregate of up to 512,500 shares of the Company’s
Common Stock at an exercise price per share equal to $0.05 (subject to adjustment as described therein) and with an expiration
date of February 23, 2028 (the “Eighth Amendment Supplemental Warrants”).
The
Existing Investors were composed of all but one of the Company’s directors as well as one of the Company’s officers
who is not also a director. Of the total amount of Eighth Amendment Supplemental Closing Notes and Eighth Amendment Supplemental
Warrants issued and sold by the Company pursuant to the Eighth Amendment, such directors and officer purchased, in aggregate,
Eighth Supplemental Closing Notes in the initial aggregate principal amount of $1,950,000 and Eighth Amendment Supplemental Warrants
to purchase an aggregate of up to 487,500 shares of our Common Stock.
The
closing date of the transaction was February 23, 2018 (the “Eighth Amendment Supplemental Closing Date”). On the Eighth
Amendment Supplemental Closing Date, each of the Eighth Amendment Investors purchased the Eighth Amendment Supplemental Closing
Notes and the Eighth Amendment Supplemental Warrants for cash, payable by wire transfer in same day funds to an account specified
by the Company.
The
Purchase Agreement and Eighth Amendment provide that the Company grant to the Eighth Amendment Investors a security interest in
the assets of the Company as collateral for payment of the Eighth Amendment Supplemental Closing Notes, evidenced by the Amended
Security Agreement and by the Amended IP Security Agreement.
The
Purchase Agreement and the Eighth Amendment Supplemental Closing Notes also provide that the Company grant registration rights
to the Eighth Amendment Investors for the Common Stock into which the Eighth Amendment Supplemental Closing Notes may be converted
and that may be issued upon exercise of the Eighth Amendment Supplemental Warrants as provided for by the Registration Rights
Agreement.
Mr.
Johnson is one of the Existing Investors. On the Eighth Amendment Supplemental Closing Date, Mr. Johnson purchased a Senior Secured
Convertible Note in the amount of $600,000 which is immediately convertible into shares of the Company’s Common Stock at
a conversion price of $0.05 per share (subject to adjustment as described therein) and has a maturity date of February 22, 2028.
In connection therewith, Mr. Johnson was also issued Eighth Amendment Supplemental Warrants for the purchase of 150,000 shares
of the Company’s Common Stock at an exercise price per share equal to $0.05 (subject to adjustment as described therein).
The Eighth Amendment Supplemental Warrants were exercisable upon issuance and have an expiration date of February 23, 2028.
CUSIP
No. 141743 10 4
|
Page
9 of 13
|
Senior
Secured Convertible Note due July 2028
On
July 13, 2018, the Company entered into a Tenth Amendment to Note and Warrant Purchase Agreement (the “Tenth Amendment”)
with the Existing Investors listed in Annex I to the Tenth Amendment (the “Tenth Amendment Investors”) and the
HealthCor Parties (solely in their capacity as majority holders (acting together with the Tenth Amendment Investors) approving
the Tenth Amendment and not as investors), pursuant to which the Company sold and issued, for an aggregate of $1,000,000 in cash,
to the Tenth Amendment Investors on such date additional notes in the initial aggregate principal amount of $1,000,000, with a
conversion price per share equal to $0.05 (subject to adjustment as described therein) and a maturity date of July 12, 2028 (the
“Tenth Amendment Supplemental Closing Notes”). The Tenth Amendment Investors were composed entirely of the Company’s
directors.
The
closing date of the transaction was July 13, 2018 (the “Tenth Amendment Supplemental Closing Date”). On the Tenth
Amendment Supplemental Closing Date, each of the Tenth Amendment Investors purchased the Tenth Amendment Supplemental Closing
Notes for cash, payable by wire transfer in same day funds to an account specified by the Company.
The
Purchase Agreement and Tenth Amendment provide that the Company grant to the Tenth Amendment Investors a security interest in
the assets of the Company as collateral for payment of the Tenth Amendment Supplemental Closing Notes, evidenced by the Amended
Security Agreement and by the Amended IP Security Agreement.
The
Purchase Agreement and the Tenth Amendment Supplemental Closing Notes also provide that the Company grant registration rights
to the Tenth Amendment Investors for the Common Stock into which the Tenth Amendment Supplemental Closing Notes may be converted
as provided for by the Registration Rights Agreement.
Mr.
Johnson is one of the Tenth Amendment Investors. On the Tenth Amendment Supplemental Closing Date, Mr. Johnson purchased a Senior
Secured Convertible Note in the amount of $500,000 which is immediately convertible into shares of the Company’s Common
Stock at a conversion price of $0.05 per share (subject to adjustment as described therein) and has a maturity date of July 12,
2028.
Item
4. Purpose of Transaction.
See
Item 3 above.
The
Reporting Persons have no plans which relate to or would result in:
(a)
the acquisition by any person of additional securities of the issuer, or the disposition of securities
of the issuer;
(b)
an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer
or any of its subsidiaries;
(c)
A sale or transfer of a material amount of assets of the issuer or of any of its subsidiaries;
(d)
Any change in the present board of directors or management of the issuer, including any plans or proposals to change the number
or term of directors or to fill any existing vacancies on the board;
(e)
Any material change in the present capitalization or dividend policy of the issuer;
CUSIP
No. 141743 10 4
|
Page
10 of 13
|
(f)
Any other material change in the issuer’s business or corporate structure, including but not limited
to, if the issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment
policy for which a vote is required by Section 13 of the Investment Company Act of 1940;
(g)
Changes in the issuer’s charter, bylaws or instruments corresponding thereto or other actions which
may impede the acquisition of control of the issuer by any person;
(h)
Causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to
be quoted in an inter-dealer quotation system of a registered national securities association;
(i)
A class of equity securities of the issuer becoming eligible for termination of registration pursuant
to Section 12(g)(4) of the Act; or
(j)
Any action similar to any of those enumerated above.
Item
5. Interest in Securities of the Issuer.
Item
5 is hereby amended and restated in its entirety as follows:
(a)
Mr.
Johnson directly owns 208,977 shares of the Company’s Common Stock. Mr. Johnson indirectly owns 15,561,616 shares of the
Company’s Common Stock through SJ Capital. Mr. Johnson directly owns 24,421,743 shares that may be acquired upon conversion
of the Fifth Amendment Supplemental Closing Note (including interest paid in kind through June 30, 2018), the Eighth Amendment
Supplemental Closing Note (including interest paid in kind through June 30, 2018) and the Tenth Amendment Supplemental Closing
Note. Mr. Johnson directly owns Warrants for the purchase of 550,001 shares and Options for the purchase of 766,667 shares exercisable
within sixty days, bringing his direct and indirect ownership to an aggregate of 41,509,004 shares. The percentage of class for
Mr. Johnson is 25.1% and is based on 165,119,159 shares which would be outstanding if all of Mr. Johnson’s Warrants and
Options were exercised and the Fifth Amendment Supplemental Closing Note, the Eighth Amendment Supplemental Closing Note and the
Tenth Amendment Supplemental Closing Note were converted.
SJ
Capital directly owns 15,561,616 shares of the Company’s Common Stock. The percentage of class for SJ Capital is 11.2% and
is based on 139,380,748 shares outstanding.
(b)
Mr. Johnson has sole power to vote or direct the vote and the power to dispose or to direct the disposition
of the 41,509,004 shares of the Company’s Common Stock owned directly or indirectly by him or to be acquired by him through
the exercise of Warrants and Options and the conversion of the Fifth Amendment Supplemental Closing Note, the Eighth Amendment
Supplemental Closing Note and the Tenth Amendment Supplemental Closing Note. (See Rows 7-10 of page 2 herein.)
Mr.
Johnson through SJ Capital has sole power to vote or direct the vote and the power to dispose or to direct the disposition of
the 15,561,616 shares of the Company’s Common Stock owned directly by SJ Capital. (See Rows 7-10 of page 3 herein.)
(c)
Please see Item 3 above for the description of the transactions relative to the shares and derivative
securities acquired by the Reporting Persons.
CUSIP
No. 141743 10 4
|
Page
11 of 13
|
(d)
The Reporting Persons know of no other person who has the right to receive or the power to direct the
receipt of dividends from, or the proceeds from the sale of, such shares or derivative securities.
(e)
Not applicable.
Item
6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities
of Issuer
Item
6 is hereby amended and restated in its entirety as follows:
Except
as outlined hereinabove, the Reporting Persons have no contracts, arrangements, understandings or relationships (legal or otherwise)
with any person with respect to any securities of the issuer, including but not limited to transfer or voting of any of the securities,
finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or
loss, or the giving or withholding of proxies.
CUSIP
No. 141743 10 4
|
Page
12 of 13
|
Item
7. Material to be Filed as Exhibits.
Item
7 is hereby amended and restated in its entirety as follows:
Exhibit
No.
|
Date
of
Document
|
Description
of Document
|
1.0
|
09/27/07
|
Securities
Exchange Agreement by and between Ecogate, Inc., CareView Communications, Inc., and Shareholders of CareView Communications,
Inc.
(1)
|
1.1
|
12/03/07
|
Non-Qualified
Stock Option, form of
(1)
|
1.2
|
09/11/09
|
CareView
Communications, Inc. 2009 Stock Incentive Plan
(1)
|
1.3
|
03/27/13
|
Securities
Purchase Agreement, form of
(2)
|
1.4
|
12/15/14
|
Fifth
Amendment to Note and Warrant Purchase Agreement between the Company and HealthCor
(3)
|
1.5
|
12/15/14
|
Form
of Fifth Amendment Supplemental Closing Note
(3)
|
1.6
|
12/15/14
|
Form
of Fifth Amendment Supplemental Warrant
(3)
|
1.7
|
02/17/15
|
Form
of Amended Pledge and Security Agreement between the Company and HealthCor Partners Fund, LP and HealthCor Hybrid Offshore
Master Fund, LP
(4)
|
1.8
|
02/17/15
|
Form
of Amended Intellectual Property Security Agreement between the Company and HealthCor Partners Fund, LP and HealthCor Hybrid
Offshore Master Fund, LP
(4)
|
1.9
|
12/07/16
|
CareView
Communications, Inc. 2016 Stock Incentive Plan
(5)
|
1.10
|
02/23/18
|
Eighth
Amendment to Note and Warrant Purchase Agreement, among the Company, HealthCor Partners Fund, LP, HealthCor Hybrid Offshore
Master Fund, LP and the investors party thereto
(6)
|
1.11
|
02/23/18
|
Form
of Eighth Amendment Supplemental Closing Note
(6)
|
1.12
|
02/23/18
|
Form
of Eighth Amendment Supplemental Warrant
(6)
|
1.13
|
07/13/18
|
Tenth
Amendment to Note and Warrant Purchase Agreement, among the Company, HealthCor Partners Fund, L.P., HealthCor Hybrid Offshore
Master Fund, L.P. and the investors party thereto
(7)
|
1.14
|
07/13/18
|
Form
of Tenth Amendment Supplemental Closing Note
(7)
|
____________________
|
(1)
|
Filed
as an exhibit to the Company’s Registration Statement on Form 10 filed with the Commission on August 23, 2010 and incorporated
herein by reference.
|
|
(2)
|
Filed
as an exhibit to the Company’s Current Report on Form 8-K filed with the Commission on March 28, 2013 and incorporated
herein by reference.
|
|
(3)
|
Filed
as an exhibit to the Company’s Current Report on Form 8-K filed with the Commission on December 19, 2014 and incorporated
herein by reference.
|
|
(4)
|
Filed
as an exhibit to the Company’s Annual Report on Form 10-K filed with the Commission on March 31, 2015 and incorporated
herein by reference.
|
|
(5)
|
Filed
as an exhibit to the Company’s Current Report on Form 8-K filed with the Commission on January 9, 2017 and incorporated
herein by reference.
|
|
(6)
|
Filed
as an exhibit to the Company’s Current Report on Form 8-K filed with the Commission on February 26, 2018 and incorporated
herein by reference.
|
|
(7)
|
Filed
as an exhibit to the Company’s Current Report on Form 8-K filed with the Commission on July 16, 2018 and incorporated
herein by reference.
|
(Signature
page follows)
CUSIP
No. 141743 10 4
|
Page
13 of 13
|
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated:
|
August
14, 2018
|
|
By:
|
/s/
Steven G. Johnson
|
|
|
|
|
Steven
G. Johnson, an individual, and as Sole Member of SJ Capital, LLC
|